Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (7495)	1/18/2000 11:22:00 AM
From: chirodoc	Read Replies (1) \| Respond to of 9719

EntreMed (ENMD) Added to The Drug and Biotech Portfolio We are adding EntreMed, Inc. (ENMD, $33) to The Bull Market Drug and Biotech Portfolio. EntreMed works in the field of cancer treatment, and has a leading position in the area of developing drugs to block "angiogenesis," a process required for tumor growth. Solid tumors require a steady blood supply for growth. Antiangiogenesis drugs target signaling processes that drive the creation of vasculature to feed tumors. When a tumor's blood supply is restricted, the tumor regresses, and at least in some cases, disappears. Nearly two years ago an electrifying front page article in the Sunday New York Times described the early development and promise of EntreMed's compounds Endostatin and Angiostatin. This thrust the company in the spotlight and made antiangiogenesis a buzzword among researchers and investors looking for a "magic bullet" in the fight against cancer. After a brief trip to the stratosphere the stock retreated as it was realized that clinical trials were still over a year away and other researchers had great difficulty in manufacturing these complex proteins. The nadir came last February when Bristol-Myers Squibb (BMY) pulled out of a collaboration to develop Angiostatin. But since then the news has been positive. Other researchers succeeded in duplicating the company's results. The company contracted with Chiron (CHIR) for a bulk supply of its lead product Endostatin for use in clinical trials, which began in late September. Thalomid, a compound licensed to Celgene Corp. (CELG), had encouraging results in Phase II studies across multiple cancer indications and is beginning to generate a royalty stream for EntreMed. Company researchers disclosed the discovery of other angiogenesis inhibitors and progress with products in preclinical development. In December, EntreMed announced that it was exercising its option to repurchase shares that had been held by Bristol-Myers, bringing a fresh burst of confidence to the stock. The year 2000 should bring growing cash flow from Thalomid sales and a steady news stream on several Thalomid cancer trials. EntreMed's 100 patient Phase I Endostatin trial should be complete by next fall, and anticipation of the results will be high. We also expect news of further developments emerging from ENMD's impressive research efforts. There are many other companies developing drugs to block angiogenesis, among them Boston Life Sciences (BLSI), Genentech (DNA), Oxigene (OXGN), and Warner Lambert (WLA). At some point in the future we will be examining these companies and others working in this field, in detail. It may be early to pick a "winner" in this space, but there are good reasons to believe that EntreMed will at least find a niche. First of all, we expect that with so many different types of cancer to treat, there will be a need for several antiangiogenic compounds. Unlike some of the other candidates in this field, Angiostatin and Endostatin are natural human proteins, and so far seem non-toxic. Also EntreMed has a strong intellectual property position in the field, with over 250 patents issued and pending.